

# Tennessee Chapter

---

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



## 2023 Pediatric ICD-10-CM Codes

*Effective October 1, 2022*

The 2023 changes to ICD-10-CM become effective on October 1, 2022. Listed below are the new codes we believe are of most interest to pediatricians. Please see your 2023 ICD-10-CM code book for a complete list of changes and to verify all new and revised codes.

### Chapter 1 Certain Infectious and Parasitic Diseases

- B37.31** Acute candidiasis of vulva and vagina
- B37.32** Chronic candidiasis of vulva and vagina

### Chapter 3 Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism

- D68.00** Von Willebrand disease, unspecified
- D68.01** Von Willebrand disease, type 1
- D68.02x** Von Willebrand disease, type 2
  - D68.020** Von Willebrand disease, type 2A
  - D68.021** Von Willebrand disease, type 2B
  - D68.022** Von Willebrand disease, type 2M
  - D68.023** Von Willebrand disease, type 2N
  - D68.029** Von Willebrand disease, type 2, unspecified
- D68.03** Von Willebrand disease, type 3
- D68.04** Acquired von Willebrand disease
- D68.09** Other von Willebrand disease

### Chapter 4 Endocrine, nutritional and metabolic diseases

- E34.30** Short stature due to endocrine disorder, unspecified
- E34.31** Constitutional short stature
- E87.2x** Acidosis

<b>E87.20</b>	Acidosis, unspecified
<b>E87.21</b>	Acute metabolic acidosis
<b>E87.22</b>	Chronic metabolic acidosis
<b>E87.29</b>	Other acidosis

## **Chapter 5 Mental, Behavioral and Neurodevelopment Disorders**

<b>F06.7x</b>	Mild neurocognitive disorder due to known physiological condition
<b>F06.70</b>	Mild neurocognitive disorder due to known physiological condition without behavioral disturbance
<b>F06.71</b>	Mild neurocognitive disorder due to known physiological condition with behavioral disturbance
<b>F10.90</b>	Alcohol use, unspecified, uncomplicated
<b>F10.91</b>	Alcohol use, unspecified, in remission
<b>F11.9x</b>	Opioid use, unspecified
<b>F11.91</b>	Opioid use, unspecified, in remission
<b>F12.91</b>	Cannabis use, unspecified, in remission
<b>F13.91</b>	Sedative, hypnotic or anxiolytic use, unspecified, in remission
<b>F14.91</b>	Cocaine use, unspecified, in remission
<b>F15.91</b>	Other stimulant use, unspecified, in remission
<b>F16.91</b>	Hallucinogen use, unspecified, in remission
<b>F18.91</b>	Inhalant use, unspecified, in remission
<b>F19.91</b>	Other psychoactive substance use, unspecified, in remission
<b>F43.8x</b>	Other reactions to severe stress
<b>F43.81</b>	Prolonged grief disorder
<b>F43.89</b>	Other reactions to severe stress
<b>F43.9</b>	Reaction to severe stress, unspecified

## **Chapter 6 Diseases of the Nervous System**

<b>G93.31</b>	Postviral fatigue syndrome
<b>G93.32</b>	Myalgic encephalomyelitis/chronic fatigue syndrome
<b>G93.39</b>	Other post infection and related fatigue syndromes

## **Chapter 14 Diseases of the genitourinary system**

**N80.0x** Endometriosis of uterus

**N80.00** Endometriosis of the uterus, unspecified

**N80.01** Superficial endometriosis of the uterus

**N80.02** Deep endometriosis of the uterus

**N80.03** Adenomyosis of the uterus

**N80.10x** Endometriosis of ovary, unspecified depth

**N80.101** Endometriosis of right ovary, unspecified depth

**N80.102** Endometriosis of left ovary, unspecified depth

**N80.103** Endometriosis of bilateral ovaries, unspecified depth

**N80.109** Endometriosis of ovary, unspecified side, unspecified depth

**N80.11x** Superficial endometriosis of the ovary

**N80.111** Superficial endometriosis of right ovary

**N80.112** Superficial endometriosis of left ovary

**N80.113** Superficial endometriosis of bilateral ovaries

**N80.119** Superficial endometriosis of ovary, unspecified ovary

**N80.12x** Deep endometriosis of ovary

**N80.121** Deep endometriosis of right ovary

**N80.122** Deep endometriosis of left ovary

**N80.123** Deep endometriosis of bilateral ovaries

**N80.129** Deep endometriosis of ovary, unspecified ovary

## **Chapter 18 Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified**

**R79.1** Abnormal coagulation profile

## **Chapter 19 Injury, Poisoning and Certain Other Consequences of External Causes**

**T43.65x** Poisoning by adverse effect of and underdosing of methamphetamines

**T43.651** Poisoning by methamphetamines accidental (unintentional)

**T43.652** Poisoning by methamphetamines intentional self-harm

**T43.653** Poisoning by methamphetamines, assault

**T43.654** Poisoning by methamphetamines, undetermined

**T43.655** Adverse effect of methamphetamines

**T43.656** Underdosing of methamphetamines

## **Chapter 20 External Causes of Morbidity**

<b>V20.0x</b>	Motorcycle driver injured in collision with pedestrian or animal in nontraffic accident
<b>V20.1x</b>	Motorcycle passenger injured in collision with pedestrian or animal in nontraffic accident
<b>V20.2x</b>	Unspecified motorcycle rider injured in collision with pedestrian or animal in nontraffic accident
<b>V20.3x</b>	Person boarding or alighting a motorcycle injured in collision with pedestrian or animal
<b>V20.4x</b>	Motorcycle driver injured in collision with pedestrian or animal in traffic accident
<b>V20.5x</b>	Motorcycle passenger injured in collision with pedestrian or animal in traffic accident
<b>V20.9x</b>	Unspecified motorcycle rider injured in collision with pedestrian or animal in traffic accident
<b>V21.0x</b>	Motorcycle driver injured in collision with pedal cycle in nontraffic accident
<b>V21.1x</b>	Motorcycle passenger injured in collision with pedal cycle in nontraffic accident
<b>V21.2x</b>	Unspecified motorcycle rider injured in collision with pedal cycle in nontraffic accident
<b>V21.3x</b>	Person boarding or alighting a motorcycle injured in collision with pedal cycle
<b>V21.4x</b>	Motorcycle driver injured in collision with pedal cycle in traffic accident
<b>V21.5x</b>	Motorcycle passenger injured in collision with pedal cycle in traffic accident
<b>V21.9x</b>	Unspecified motorcycle rider injured in collision with pedal cycle in traffic accident
<b>V22.xx</b>	Motorcycle rider injured in collision with two- or three-wheeled motor vehicle
<b>V23.xx</b>	Motorcycle rider injured in collision with car, pick-up truck or van
<b>V24.xx</b>	Motorcycle rider injured in collision with heavy transport vehicle or bus
<b>V25.xx</b>	Motorcycle rider injured in collision with railway train or railway vehicle
<b>V26.xx</b>	Motorcycle rider injured in collision with other nonmotor vehicle
<b>V27.xx</b>	Motorcycle rider injured in collision with fixed or stationary object
<b>V28.xx</b>	Motorcycle rider injured in noncollision transport accident
<b>V29.xx</b>	Motorcycle rider injured in other and unspecified transport accidents

**(See 4<sup>th</sup> and 5<sup>th</sup> character requirements for codes V20.0-V29. 7<sup>th</sup> character also required.)**

## **Chapter 21 Factors Influencing Health Status and Contact with Health Services**

<b>Z59.82</b>	Transportation insecurity
<b>Z59.86</b>	Financial insecurity
<b>Z59.87</b>	Material hardship
<b>Z71.87</b>	Encounter for pediatric-to-adult transition counseling
<b>Z79.6</b>	Long term (current) use of immunomodulators and immunosuppressants

- Z79.62x** Long term (current) use of immunosuppressant
- Z79.63x** Long term (current) use of chemotherapeutic agent
- Z79.64** Long term (current) use of myelosuppressive agent
- Z79.69** Long term (current) use of other immunomodulators and immunosuppressants
- Z79.85** Long-term (current) use of injectable non-insulin antidiabetic drugs

\*\*\*\*\*Disclaimer\*\*\*\*\*

The Tennessee Chapter of the American Academy of Pediatrics (TNAAP) is not affiliated with any other organization, vendor, or company. The information contained herein is intended for educational purposes only, and any other use (including, without limitation, reprint, transmission or dissemination in whole or in part) is strictly prohibited. Although reasonable attempts have been made to provide accurate and complete information, neither the publisher nor any person associated with TNAAP warrant or guarantee the information contained herein is correct or applicable for any particular situation. TNAAP will not undertake to update any information provided herein. In all cases, the practitioner or provider is responsible for use of this educational material, and any information provided should not be a substitution for the professional judgment of the practitioner or provider.

Resources: *ICD-10-CM 2023*